News & Updates
Filter by Specialty:

Osimertinib reduces risk of metastasis, CNS progression in NSCLC
13 Dec 2024
byStephen Padilla
Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.
Osimertinib reduces risk of metastasis, CNS progression in NSCLC
13 Dec 2024
Why not metformin for long COVID in non-diabetics?
03 Dec 2024
byElvira Manzano
Metformin prescribed within a week of SARS-CoV-2 infection was associated with a 53-percent reduction in long COVID or death over 6 months in patients without diabetes or prediabetes, as shown in a simulation study presented at IDWeek 2024.